Prematür ejakülasyon: Güncel tedavi ve gelecek

Prematür ejakülasyon (PE), erkekler arasında en yaygın cinsel işlev bozukluğudur. Premtür ejakülasyon patofizyolojisi’nin multifaktöriyel özelliği PE’yi başarılı bir şekilde tedavi etmek için multimodal terapötik rejimlere ihtiyaç olduğunu göstermektedir. Multipl tedavi rejimlerinin penetrasyon ve ejakülasyon arasındaki süreyi uzatmada etkili olduğu gösterilmiştir. Bu tedavi yöntemleri, davranış değişiklikleri ve ilaçlardan, diyet değişiklikleri ve majör cerrahilere kadar her şeyi içerir. Bu makalenin amacı, PE tedavisinde yaygın olarak kullanılan tedavi rejimlerini gözden geçirmek ve PE tedavisi için en yeni tedavi modalitelerini ve gelecek tedavi perspektiflerini tanıtmak ve tartışmaktır.

Premature ejaculation: current and future treatments

Premature ejaculation is the most common form of sexual dysfunction among men. The pathophysiology of premature ejaculation appears to be multifactorial, implicating the need for multimodal therapeutic regimens to successfully treat prematüre ejaculation. Multiple treatment regimens have been shown to be effective in extending the time between penetration and ejaculation. These treatment modalities include everything from behavioral modifications and medications to diet alterations and majör surgery. The goal of the present article was to review the commonly used treatment regimens used in the treatment of premature ejaculation, as well as to introduce and discuss the newest treatment modalities and future treatment perspectives for premature ejaculation.

PDF

___

1. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med 2005;2:358–67. [CrossRef]
2. Ehrentheil OF. A case of premature ejaculation in Greek mythology. J Sex Res 1974;10:128–31. http://www.jstor.org/stable/3811282
3. Gross S. Practical Treatise on Impotence and Sterility and Allied Disorders of the Male Sexual Organs. Edinburg, YJ: Pentland; 1887.
4. Krafft-Ebing R. Psychopathia sexualis, 11th ed. Stutgart: Enke; 1901.
5. Abraham K. Über Ejaculatio Praecox. Zeitschr Aerztliche Psychoanalyse 1917;4:171–86. https://pep-web.org/search/ document/IZPA.004.0171A?page=P0171
6. Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation. Sex Med 2014;2:41–59. [CrossRef]
7. Waldinger MD. History of premature ejaculation. In: Jannini EA, McMahon CG, Waldinger MD, editors. Premature ejaculation: From etiology to diagnosis and treatment. New York: Springer; 2013. p.5–24. [CrossRef]
8. Schapiro B. Premature Ejaculation: a review of 1130 cases. J Urol 1943;50:374–9. [CrossRef]
9. Master, WH, Johnson VE. Premature Ejaculation. In: Master WH, Johnson VE, editors. Human sexual inadequacy. Boston: Little, Brown and Co.; 1970.
10. Semans JH. Premature Ejaculation: a new approach. South Med J 1956;49:353–8. [CrossRef]
11. St Lawrence JS, Madakasira S. Evaluation and treatment of premature ejaculation: a critical review. Int J Psychiatry Med 1992;22:77–97. [CrossRef]
12. PräJaculin SB. Kombiniertes epiphysen-präparat gegen reizzustände am genitale und hypererotismus. Hamburg: Chemische Farbrik Promonta GmbH; 1932.
13. Eaton H. Clomipramine (Anafranil) in the Treatment of Premature Ejaculation. Int J Med Res 1973;1:432–4. [CrossRef]
14. Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998;92:111–8. [CrossRef]
15. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol 2002;168:2359–67. [CrossRef]
16. Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, et al. EAU Guidelines on Sexual and Reproductive Health. Edn. presented at the EAU Annual Congress Milan 2021 978-94- 92671-13-4. Arnhem, The Netherlands: EAU Guidelines Office; 2021.
17. Giuliano F. 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci 2007;30:79–84. [CrossRef]
18. Olivier B, van Oorschot R, Waldinger MD. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol 1998;13 Suppl 6:S9–14. [CrossRef]
19. Waldinger MD, van De Plas A, Pattij T, van Oorschot R, Coolen LM, Veening JG, Olivier B. The selective serotonin reuptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment. Psychopharmacology 2002;160:283–9. [CrossRef]
20. Kiliç S, Ergin H, Baydinç YC. Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. Int J Androl 2005;28:47–52. [CrossRef]
21. McMahon CG. Long term results of treatment of premature ejaculation with selective serotonin re-uptake inhibitors. Int J Impot Res 2002;14:S19.
22. Martin C, Nolen H, Podolnick J, Wang R. Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going. Int J Urol 2017;24:40–50. [CrossRef]
23. van Geffen ECG, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts ACG. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005;61:303–7. [CrossRef]
24. Lee J. Potential Risks for the Off-label Use of SSRIs in Premature Ejaculation (CME). J Sex Med 2010;7:2622–4;quiz 2625. [CrossRef]
25. Montague DK, Jarow J, Broderick GA, Dmochowski RR, JP Heaton W, Lue TF, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004;172:290–4. [CrossRef]
26. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62 Suppl 3:10–21. https://pubmed.ncbi.nlm.nih.gov/11229449/
27. Koyuncu H, Serefoglu EC, Ozdemir AT, Hellstrom WJ. Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation. Int J Impot Res 2012;24:171–3. [CrossRef]
28. Cohen D. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned? Psychother Psychosom 2007;76:5–14. [CrossRef]
29. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007;164:1044–9. [CrossRef]
30. Dresser MJ, Kang D, Staehr P, Gidwani S, Guo C, Mulhall JP, Modi NB. Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal. J Clin Pharmacol 2006;46:1023–9. [CrossRef]
31. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med 2011;8:524–39. [CrossRef]
32. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res 2006;18:104–10. [CrossRef]
33. Levine L. Evaluation of withdrawal effects with dapoxetine in the treatment of premature ejaculation (PE). Poster presented at SMSNA 2006.
34. El-Say KM, Ahmed OA, Mohamed AI, Safo MK, Omar AM. Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation. Int J Nanomed 2019;14:7461–73. [CrossRef]
35. Ahmed TA, Alay AMS, Okbazghi SZ, Alhakamy NA. Two-Step Optimization to Develop a Transdermal Film Loaded With Dapoxetine Nanoparticles: A Promising Technique to Improve Drug Skin Permeation. Dose Response 2020;18:1559325820923859. [CrossRef]
36. Ozcan L, Polat EC, Otunctemur A, Ozbek E. Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation. Int Urol Nephrol 2015;47:283–7. [CrossRef]
37. Athanasios Z, Polyanthi P, George K. The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol 2007;39:115–8. [CrossRef]
38. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007;151:737–48. [CrossRef]
39. Waldinger MD. Drug treatment options for premature ejaculation. Exp Opin Pharmacother 2018;19:1077–85. [CrossRef]
40. Strassberg DS, de Gouveia Brazao CA, Rowland DL, Tan P, Slob AK. Clomipramine in the treatment of rapid (premature) ejaculation. J Sex Marital Ther 1999;25:89–101. [CrossRef]
41. Segraves RT, Saran A, Segraves K, Maguire E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther 1993;19:198–200. [CrossRef]
42. Althof SE, Levine SB, Corty EW, Risen CB, Stern EB, Kurit DM. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry 1995;56:402–7. https://pubmed. ncbi.nlm.nih.gov/7665538/
43. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a doubleblind, placebo controlled study. J Urol 1998;159:425–7. [CrossRef]
44. Ogata J, Minami K, Uezono Y, Okamoto T, Shiraishi M, Shigematsu A, Ueta Y. The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesthesia Analgesia 2004;98:1401–6, table of contents. [CrossRef]
45. Khan AH, Rasaily D. Tramadol use in premature ejaculation: daily versus sporadic treatment. Indian J Psychol Med 2013;35:256–9. [CrossRef]
46. Wu T, Yue X, Duan X, Luo D, Cheng Y, Tian Y, Wang K. Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis. Urology 2012;80:618–24. [CrossRef]
47. Kirby EW, Carson CC, Coward RM. Tramadol for the management of premature ejaculation: a timely systematic review. Int J Impot Res 2015;27:121–7. [CrossRef]
48. McMahon CG. Current and Emerging Treatments for Premature Ejaculation. Sex Med Rev 2015;3:183–202. [CrossRef]
49. Shinghal R, Barnes A, Mahar KM, Stier B, Giancaterino L, Condreay LD, et al. Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study. J Sex Med 2013;10:2506–17. [CrossRef]
50. McMahon C, Althof S, Rosen R, Giuliano F, Miner M, Osterloh IH, et al. The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-ofConcept Trial (PEPIX). J Sex Med 2019;16:1178–87. [CrossRef]
51. Althof S, Osterloh IH, Muirhead GJ, George K, Girard N; PEDRIX Multi-Centre Study Group. The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, DoubleBlind, Placebo-Controlled Phase IIb trial (PEDRIX). J Sex Med 2019;16:1188–98. [CrossRef]
52. Başar MM, Yilmaz E, Ferhat M, Başar H, Batislam E. Terazosin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol 2005;37:773–7. [CrossRef]
53. Cavallini G. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol 1995;28:126–30. [CrossRef]
54. Akin Y, Gulmez H, Ates M, Bozkurt A, Nuhoglu B. Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial. Iran Red Crescent Med J 2013;15:e13805. [CrossRef] 55. Debruyne FM, Van der Poel HG. Clinical experience in Europe with uroselective alpha1-antagonists. Eur Urol 1999;36 Suppl 1:54–8; discussion 65. [CrossRef]
56. McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 2006;98:259– 72. [CrossRef]
57. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol 2007;52:1331–9. [CrossRef]
58. McMahon CG, Stuckey BGA, Andersen M, Purvis K, Koppiker N, Haughie S, Boolell M. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005;2:368–75. [CrossRef]
59. Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001;13:41–5. [CrossRef]
60. Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002;168:2486–9. [CrossRef]
61. Xin ZC, Chung WS, Choi YD, Seong DH, Choi YJ, Choi HK. Penile sensitivity in patients with primary premature ejaculation. J Urol 1996;156:979–81. [CrossRef]
62. Yagiela JA. Vasoconstrictor agents for local anesthesia. Anesth Prog 1995;42:116–20. https://www.ncbi.nlm.nih.gov/labs/pmc/ articles/PMC2148913/pdf/anesthprog00243-0053.pdf
63. Wyllie MG, Powell JA. The role of local anaesthetics in premature ejaculation. BJU Int 2012;110:E943–8. [CrossRef]
64. Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocainelidocaine cream in the treatment of premature ejaculation. J Urol 1995;154:1360–1. https://pubmed.ncbi.nlm.nih.gov/7658537/
65. Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocainelidocaine cream in premature ejaculation. Andrologia 2002;34:356–9. [CrossRef]
66. Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebocontrolled study. BJU Int 2004;93:1018–21. [CrossRef]
67. Henry R, Morales A, Wyllie MG. TEMPE: Topical EutecticLike Mixture for Premature Ejaculation. Exp Opin Drug Deliv 2008;5:251–61. [CrossRef]
68. Choi JB, Kang SH, Lee DH, Kim YS, Jeon J-S, Choi WS, Kim SW. Efficacy and Safety of On Demand Clomipramine for the Treatment of Premature Ejaculation: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial. J Urol 2019;201:147–52. [CrossRef]
69. Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 2007;99:369–75. [CrossRef]
70. Porst H, Burri A. Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review. Sex Med Rev 2019;7:129–40. [CrossRef]
71. Gilbert R. Promescent. Absorption Pharmaceuticals, LLC (Online), 2015. https://www.promescent.com/about-promescent/ promescent-and-psd-502
72. Mark KP, Kerner I. Event-level impact of Promescent on quality of sexual experience in men with subjective premature ejaculation. Int J Impot Res 2016;28:216–20. [CrossRef]
73. Garcia F, Capomacchia A, Kongkeo S, Brock G. Non-medical components are an important factor in drug delivery in topical therapies: a study of topical lidocaine therapy for premature ejaculation. Proceedings of the 20th Annual Fall Scientific Meeting. Miami Beach, USA; 2014.
74. Xin ZC, Choi YD, Seong DH, Choi HK. Sensory evoked potential and effect of SS-cream in premature ejaculation. Yonsei Med J 1995;36:397–401. [CrossRef]
75. Xin ZC, Choi YD, Lee WH, Chun DC, Choi HK, et al. Changes in ejaculatory latency and penile vibratory threshold with SS-cream in patients with primary premature ejaculation. Sex Dysfunct 1998;1:89–93. [CrossRef]
76. Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy. Behav Res Ther 1986;24:665–75. [CrossRef]
77. Althof S. The psychology of premature ejaculation: therapies and consequences. J Sex Med 2006;3 Suppl 4:324–31. [CrossRef]
78. Perelman MA. A new combination treatment for premature ejaculation: a sex therapist’s perspective. J Sex Med 2006;3:1004– 12. [CrossRef]
79. Tsai M-Y, Liu C-T, Chang C-C, Chen S-Y, Huang S-T. Overview of the relevant literature on the possible role of acupuncture in treating male sexual dysfunction. Acupunct Med 2014;32:406–10. [CrossRef]
80. Sunay D, Sunay M, Aydoğmuş Y, Bağbancı S, Arslan H, Karabulut A, Emir L. Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial. Eur Urol 2011;59:765–71. [CrossRef]
81. Li T, Tan Y, Xie Z, Wang W, Wang S, Ouyang H, et al. Clinical efficacy of Paroxetine combined with mid-frequency electrical pulse acupoint stimulation for premature ejaculation. Zhonghua Nan Ke Xue 2015;21:921–4. https://pubmed.ncbi.nlm.nih. gov/26665683/
82. Sahin S, Bicer M, Yenice MG, Seker KG, Yavuzsan AH, Tugcu V. A Prospective Randomized Controlled Study to Compare Acupuncture and Dapoxetine for the Treatment of Premature Ejaculation. Urol Int 2016;97:104–11. [CrossRef]
83. Dhikav V, Karmarkar G, Gupta M, Anand KS. Yoga in premature ejaculation: a comparative trial with fluoxetine. J Sex Med 2007;4:1726–32. [CrossRef]
84. Mamidi P, Gupta K. Efficacy of certain yogic and naturopathic procedures in premature ejaculation: A pilot study. Int J Yoga 2013;6:118–22. [CrossRef]
85. Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002;68:107–12. [CrossRef]
86. Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert FA, Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000;39:1974–83. [CrossRef]
87. Korotkova TM, Klyuch BP, Ponomarenko AA, Lin JS, Haas HL, Sergeeva OA. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007;52:626–33. [CrossRef]
88. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155–88. https:// pubmed.ncbi.nlm.nih.gov/6119708/
89. Serefoglu EC, Silay MS. Botulinum toxin-A injection may be beneficial in the treatment of life-long premature ejaculation. Med Hypotheses 2010;74:83–4. [CrossRef]
90. Gaxiola GM, Aguilar IE, Paz GP. Method for treating premature ejaculation with a botulinum neurotoxin. USA2012 [US 8329193B2]. [Erişim]
91. Szallasi A, Blumberg PM. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience 1989;30:515–20. [CrossRef]
92. Shi B, Li X, Chen J, Su B, Li X, Yang S, et al. Resiniferatoxin for treatment of lifelong premature ejaculation: a preliminary study. Int J Urol 2014;21:923–6. [CrossRef]
93. Yan W-J, Yu N, Yin T-L, Zou Y-J, Yang J. A new potential risk factor in patients with erectile dysfunction and premature ejaculation: folate deficiency. Asian J Androl 2014;16:902–6. [CrossRef]
94. Yin T-L, Yang J, Zhang B, Yan W-J, Xu W-M, Li W, et al. Folic acid supplementation as adjunctive treatment premature ejaculation. Med Hypotheses 2011;76:414–6. [CrossRef]
95. Karabakan M, Erkmen AE, Guzel O, Aktas BK, Bozkurt A, Akdemir S. Association between serum folic acid level and erectile dysfunction. Andrologia 2016;48:532–5. [CrossRef]
96. Hamidi Madani A, Asadolahzade A, Mokhtari G, Shahrokhi Damavand R, Farzan A, Esmaeili S. Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. J Sex Med 2013;10:1146–50. [CrossRef]
97. Saadat SH, Ahmadi K, Panahi Y. The effect of on-demand caffeine consumption on treating patients with premature ejaculation: a double-blind randomized clinical trial. Curr Pharm Biotechnol 2015;16:281–7. [CrossRef]
98. Zavatti M, Zanoli P, Benelli A, Rivasi M, Baraldi C, Baraldi M. Experimental study on Satureja montana as a treatment for premature ejaculation. J Ethnopharmacol 2011;133:629–33. [CrossRef]
99. Corona G, Jannini EA, Lotti F, Boddi V, De Vita G, Forti G, et al. Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Int J Androl 2011;34:41–8. [CrossRef]
100.Mohseni MG, Hosseini SR, Alizadeh F, Rangzan N. Serum testosterone and gonadotropins levels in patients with premature ejaculation: A comparison with normal men. Adv Biomed Res 2014;3:6. [CrossRef]
101.Basal S, Goktas S, Ergin A, Yildirim I, Atim A, Tahmaz L, Dayanc M. A novel treatment modality in patients with premature ejaculation resistant to conventional methods: the neuromodulation of dorsal penile nerves by pulsed radiofrequency. J Androl 2010;31:126–30. [CrossRef]
102.Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, et al. An Update of the International Society of Sex Med’s Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE). Sex Med 2014;2:60–90. [CrossRef ]
103.Zhou X-J, Zhang Z-G, Hao L, Zhang W-D, Dong B-Z, Han C-H. Elective microscopic resection of dorsal penile nerves for primary premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue 2013;19:1003–6. https://pubmed.ncbi.nlm.nih. gov/24341095/
104.Seftel AD. Re: percutaneous CT-guided cryoablation of the dorsal penile nerve for treatment of symptomatic premature ejaculation. J Urol 2013;189:1836–7. [CrossRef]
105.Littara A, Palmieri B, Rottigni V, Iannitti T. A clinical study to assess the effectiveness of a hyaluronic acid-based procedure for treatment of premature ejaculation. Int J Impot Res 2013;25:117– 20. [CrossRef]
106.Moon DG, Kwak T Il, Kim JJ. Glans Penis Augmentation Using Hyaluronic Acid Gel as an Injectable Filler. World J Mens Health 2015;33:50–61. [CrossRef]
107.Song B, Hou Z, Liu Q, Qian W. Penile frenulum lengthening for premature ejaculation. Zhonghua Nan Ke Xue 2015;21:149–52. https://pubmed.ncbi.nlm.nih.gov/25796689/
108.Ahmed A-F, Abdel-Aziz A-S, Maarouf AM, Ali M, Emara A-A, Gomaa A. Impact of varicocelectomy on premature ejaculation in varicocele patients. Andrologia 2015;47:276–81. [CrossRef]
109.Li H-C, Zhang L-D, Gao M, Chong T, Deng Q, Yin J, Wang Z-M. Spermatic vein ligation and intra-vaginal ejaculation latency. Zhonghua Nan Ke Xue 2014;20:531–5. https://pubmed.ncbi. nlm.nih.gov/25029860/
110.Gao J, Xu C, Zhang J, Liang C, Su P, Peng Z, et al. Effects of adult male circumcision on premature ejaculation: results from a prospective study in China. Biomed Res Int 2015;2015:417846. [CrossRef]
111. Morris BJ, Krieger JN. Does male circumcision affect sexual function, sensitivity, or satisfaction? --a systematic review. J Sex Med 2013;10:2644–57. [CrossRef]
112. Tian Y, Liu W, Wang J-Z, Wazir R, Yue X, Wang K-J. Effects of circumcision on male sexual functions: a systematic review and meta-analysis. Asian J Androl 2013;15:662–6. [CrossRef]
113. Cox G, Krieger JN, Morris BJ. Histological Correlates of Penile Sexual Sensation: Does Circumcision Make a Difference? Sex Med 2015;3:76–85. [CrossRef]
114. La Pera G. Awareness and timing of pelvic floor muscle contraction, pelvic exercises and rehabilitation of pelvic floor in lifelong premature ejaculation:5 years experience. Arch Ital Urol Androl 2014;86:123–5. [CrossRef]
115. Pastore AL, Palleschi G, Fuschi A, Maggioni C, Rago R, Zucchi A, et al. Pelvic floor muscle rehabilitation for patients with lifelong premature ejaculation: a novel therapeutic approach. Ther Adv Urol 2014;6:83–8. [CrossRef]
116. Pastore AL, Palleschi G, Leto A, Pacini L, Iori F, Leonardo C, et al. A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. Int J Androl 2012;35:528–33. [CrossRef]
117. Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, et al. Behavioral Therapies for Management of Premature Ejaculation: A Systematic Review. Sex Med 2015;3:174–88. [CrossRef]
118.Ma G-C, Zou Z-J, Lai Y-F, Zhang X, Zhang Y. Regular penisroot masturbation, a novel behavioral therapy in the treatment of primary premature ejaculation. Asian J Androl 2019;21:631–4. [CrossRef]
119. Food and Drug Administration, HHS. Medical devices; gastroenterology-urology devices; classification of the vibrator for climax control of premature ejaculation. Final order. Fed Regist 2015;80:30353–5. https://www.govinfo.gov/content/pkg/FR2015-05-28/pdf/2015-12852.pdf
120.Ventus D, Gunst A, Arver S, Dhejne C, Öberg KG, ZamoreSöderström E, et al. Vibrator-Assisted Start-Stop Exercises Improve Premature Ejaculation Symptoms: A Randomized Controlled Trial. Arch Sex Behav 2020;49:1559–73. [CrossRef]
121. Rodríguez JE, Marzo JC, Piqueras JA. Efficacy of Sphincter Control Training (SCT) in the treatment of premature ejaculation, a new cognitive behavioral approach: A parallel-group randomized, controlled trial. PloS One 2019;14:e0212274. [CrossRef]
122. Shechter A, Serefoglu EC, Gollan T, Springer S, Meiry G, Appel B, Gruenwald I. Transcutaneous functional electrical stimulation-a novel therapy for premature ejaculation: results of a proof of concept study. Int J Impot Res 2020;32:440–5. [CrossRef]